金斯瑞生物科技(01548.HK) 公布截至去年12月底止全年业绩，持续经营业务收益5.94亿美元(下同)，按年升6.1%；亏转盈赚29.62亿元，上年同期蚀9,547.7万元；年内持续经营业务亏损1.73亿元，上年同期录利润1.62亿元；每股盈利139.63美分，至于持续经营业务的每股亏损为8.19美分。不派息。
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/09 | 中期业绩 | 无派息 |
| 2024/03/10 | 末期业绩 | 无派息 |
| 2023/08/20 | 中期业绩 | 无派息 |
| 2023/03/31 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.